Financial reports
10-Q
2022 Q1
Quarterly report
6 May 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
10-K
2021 FY
Annual report
10 Mar 22
10-Q
2021 Q3
Quarterly report
5 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
7 May 21
10-K
2020 FY
Annual report
11 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
Current reports
8-K
Termination of a Material Definitive Agreement
1 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 22
8-K
Other Events
22 Jun 22
8-K
Other Events
1 Jun 22
8-K
Sierra Oncology Reports First Quarter 2022 Results
6 May 22
8-K
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
13 Apr 22
8-K
Departure of Directors or Certain Officers
22 Mar 22
8-K
Sierra Oncology Reports 2021 Year End Results
10 Mar 22
8-K
Departure of Directors or Certain Officers
7 Mar 22
8-K
Other Events
27 Jan 22
Registration and prospectus
15-12G
Securities registration termination
11 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
POS AM
Prospectus update (post-effective amendment)
1 Jul 22
POS AM
Prospectus update (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
Proxies
DEFM14A
Proxy related to merger
16 May 22
PREM14A
Preliminary proxy related to merger
29 Apr 22
DFAN14A
Additional proxy materials by non-management
13 Apr 22
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEFA14A
Additional proxy soliciting materials
3 Jun 21
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
DEFA14A
Additional proxy soliciting materials
26 May 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
Other
EFFECT
Notice of effectiveness
8 Jul 22
EFFECT
Notice of effectiveness
8 Jul 22
EFFECT
Notice of effectiveness
12 Nov 21
CORRESP
Correspondence with SEC
10 Nov 21
UPLOAD
Letter from SEC
9 Nov 21
EFFECT
Notice of effectiveness
14 Aug 20
CORRESP
Correspondence with SEC
11 Aug 20
UPLOAD
Letter from SEC
10 Aug 20
CT ORDER
Confidential treatment order
30 Nov 18
EFFECT
Notice of effectiveness
22 Jun 18
Ownership
SC 13G/A
Rock Springs Capital Management LP
14 Feb 23
SC 13G/A
Versor Investments LP
10 Feb 23
SC 13D/A
Abingworth LLP
11 Jul 22
SC 13G/A
Vivo Capital IX, LLC
5 Jul 22
4
Change in insider ownership
1 Jul 22
4
Change in insider ownership
1 Jul 22
4
Mona Ashiya
1 Jul 22
4
Gaurav Aggarwal
1 Jul 22
4
Andrew Sinclair
1 Jul 22
4
Barbara Klencke
1 Jul 22